Supplemental material
Human Vaccines & Immunotherapeutics
Volume 17, 2021 - Issue 5
Research Paper
A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults
Antonios O. Aliprantisa Merck & Co., Inc., Kenilworth, NJ, USA
https://orcid.org/0000-0002-8744-2535View further author information
https://orcid.org/0000-0002-8744-2535View further author information, Christine A. Shawb Moderna, Inc., Cambridge, MA, USAhttps://orcid.org/0000-0002-0471-206XView further author information
https://orcid.org/0000-0002-0471-206XView further author information, Paul Griffinc QPharm, Herston, Australia;d The University of Queensland, Brisbane, Australia;e Mater Research Raymond Terrace, South Brisbane, Australiahttps://orcid.org/0000-0002-1656-421XView further author information
https://orcid.org/0000-0002-1656-421XView further author information, Nicholas Farinolaf CMAX, Adelaide, Australiahttps://orcid.org/0000-0002-9855-6984View further author information
https://orcid.org/0000-0002-9855-6984View further author information, , Xin Caoa Merck & Co., Inc., Kenilworth, NJ, USAhttps://orcid.org/0000-0002-7633-845XView further author information
https://orcid.org/0000-0002-7633-845XView further author information, , Jeffrey R. Sachsa Merck & Co., Inc., Kenilworth, NJ, USAhttps://orcid.org/0000-0001-5725-558XView further author information
https://orcid.org/0000-0001-5725-558XView further author information, Christine J. Swensonb Moderna, Inc., Cambridge, MA, USAhttps://orcid.org/0000-0002-4693-2597View further author information
https://orcid.org/0000-0002-4693-2597View further author information, Heather Leeb Moderna, Inc., Cambridge, MA, USAhttps://orcid.org/0000-0002-7310-341XView further author information
https://orcid.org/0000-0002-7310-341XView further author information, Kara S. Coxa Merck & Co., Inc., Kenilworth, NJ, USAhttps://orcid.org/0000-0002-5798-2944View further author information
https://orcid.org/0000-0002-5798-2944View further author information, , , Igor Smolenovb Moderna, Inc., Cambridge, MA, USAhttps://orcid.org/0000-0002-7075-9827View further author information
https://orcid.org/0000-0002-7075-9827View further author information, , , Amy S. Espesetha Merck & Co., Inc., Kenilworth, NJ, USAhttps://orcid.org/0000-0003-2213-909XView further author information
https://orcid.org/0000-0003-2213-909XView further author information & Lori Pantherb Moderna, Inc., Cambridge, MA, USACorrespondence[email protected]
https://orcid.org/0000-0002-8223-9167View further author information
https://orcid.org/0000-0002-8223-9167View further author information show all